Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HLA-matched multivirus-specific T cells
- Development stage
- Phase 2
- Lead developer
- Baylor College of Medicine
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
HLA-matched multivirus-specific T cells (VSTs) is an investigational off-the-shelf adoptive cellular immunotherapy developed by Baylor College of Medicine. The therapy consists of allogeneic cytotoxic T lymphocytes (CTLs) derived from healthy donors that have been expanded and trained to recognize specific antigens from five common opportunistic viruses: Epstein-Barr virus (EBV), cytomegalovirus (CMV), adenovirus (AdV), BK virus (BKV), and JC virus (JCV). These VSTs are stored in a bank and selected for patients based on partial HLA matching. The primary indication is the treatment of persistent or drug-resistant viral infections in immunocompromised individuals, particularly those who have undergone allogeneic hematopoietic stem cell transplantation (HSCT) or received CAR-T cell therapy. The therapy works by recognizing and killing virus-infected cells through the specific targeting of viral antigens. The commercialized version of this multi-virus T-cell technology is known as posoleucel.
- Brand names
- Posoleucel
- Other names
- Multivirus-specific cytotoxic T-lymphocytesOff-the-shelf VSTsPartially HLA-matched VSTs5-virus VSTs
02
Targets
AdV-peptide-HLA (Adenovirus-derived peptide–HLA complexes)BK virus-derived peptide-HLA complexesCytomegalovirus-derived peptide-human leukocyte antigen complexespMHC (Peptide-MHC complex family)Human herpesvirus 6-derived peptide-human leukocyte antigen complexesInfluenza virus-derived peptide-human leukocyte antigen complexes (pHLA complexes)JC virus-derived peptide-HLA complexesRespiratory syncytial virus-derived peptide-HLA complexes
Beyond the preview
Go deeper on HLA-matched multivirus-specific T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HLA-matched multivirus-specific T cells.